Aibo Hechuang has recently declared the successful closure of its Series A+ equity financing round, raising tens of millions of yuan. This round was spearheaded by Puhe Capital, with strategic co-investment from Longgang Financial Holdings. The newly acquired funds will be strategically allocated to broaden the application scope and facilitate the market introduction of vascular interventional surgical robots. Additionally, the investment will expedite the R&D and registration processes for intelligent automated surgical systems and remote surgical systems, while also bolstering the recruitment and development of a talented workforce.

Established in 2020 by Professor Guo Shuxiang and his team, Aibo Hechuang is dedicated to the R&D and industrialization of vascular interventional surgical robots. The company has developed a comprehensive pan-vascular interventional robot platform that spans the entire procedural spectrum across various interventional domains. Leveraging its proprietary five-channel array-driven system, Aibo Hechuang has established substantial platform-based architectural advantages. In 2024, its first-generation cerebrovascular interventional surgical assistance operating system obtained Class III medical device registration certification from the National Medical Products Administration (NMPA). This system has been successfully implemented in over ten top-tier hospitals for clinical use, yielding outstanding clinical research outcomes. Moreover, the clinical trial data for the coronary interventional surgical control system has also demonstrated exceptional performance.

Furthermore, Aibo Hechuang has set numerous global and domestic benchmarks in the realm of remote vascular interventional surgery. The company is actively propelling the R&D of intelligent automated surgical systems, with a portfolio of over 580 domestic and international patents already filed. Having previously secured multiple rounds of investment from diverse institutions, Aibo Hechuang is poised to capitalize on the strengths of its pan-vascular platform. The company aims to secure a preeminent position in the global race for fully automated vascular interventional surgical robots.